Resverlogix Corp.

Sep 05, 2017

Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement

Aug 28, 2017

Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction

Jul 25, 2017

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Jul 10, 2017

Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

Jun 28, 2017

Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Jun 05, 2017

Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

May 30, 2017

Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone